The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery

Sponsor
Horizon Health Network (Other)
Overall Status
Completed
CT.gov ID
NCT01073995
Collaborator
(none)
54
1
2
68
0.8

Study Details

Study Description

Brief Summary

The median Orthopaedic surgery wait time in Canada is 36.7 weeks (Esmail 2008), thus there is a need to find alternative treatments for pathologies such as lumbar disc herniations (LDH). The literature has demonstrated that selective nerve root injections (SNRI) are able to alleviate sciatic symptoms caused by LDH (Riew 2006) and may be beneficial as an alternative to surgery. It is necessary to determine whether SNRIs provide significant symptom resolution alleviating the need for surgery, or to determine if their success is transient and delays the time to surgery. The purpose of the proposed study is to evaluate the success of SNRI in patients suffering with LDH and to determine which factors influence outcome. Over the span of 2 years, data from 100 patients will be collected. These patients will be surgical candidates and have exhausted all non-operative measures prior to receiving a SNRI. Upon first assessment, each eligible patient will be randomly assigned to the treatment (steroid) or control (saline) group. The patient and all treating physicians will be blinded to the treatment given. Each patient will be followed over their course of treatment and information pertaining to their pain and symptoms will be recorded using standard questionnaires. Patient demographics, diagnosis, Worker's Compensation status, spinal levels treatment/outcome, and time from referral to treatment will also be evaluated. The primary outcome measure will be defined as the avoidance of surgery.

Condition or Disease Intervention/Treatment Phase
  • Drug: Kenalog and Sensorcaine
Phase 3

Detailed Description

Patient Selection: All patients (ages 18-65 years) who have been diagnosed with lower extremity radiculopathy (sciatica) secondary to a lumbar disc herniation that have been referred for SNRI by the principal investigator (Dr. Neil Manson) will be asked to participate in the study. All patients will have exhausted non-operative measures.

Initial Assessment: During the initial office visit, patients will be assessed by the principle investigator for inclusion in the study. If the patient demonstrates interest in the proposed research they will be provided a Consent Form and given the opportunity to ask a Research Assistant questions regarding their participation.

. Injections: Standard procedures for SNRI will be used by the participating Radiologists in the Department of Radiology at the Saint John Regional Hospital. Each patient will be randomly assigned by a Research Assistant to either the treatment (Kenalog/Sensorcaine) or control (Saline) group. All treatments will be blinded to the treating physicians and the patient.

Injectates: Control Group: Saline Treatment Group: Kenalog 40cc/0.25% Sensorcaine

Follow up assessment: During a follow-up visit, patients will be re-assessed to determine the success of the injection. SNRI success will be determined by self-reported pain and symptom reduction. If the patient and principle investigator do not deem the injection successful, further treatment options will be discussed (second injection, surgery, etc) and follow-up evaluations will be scheduled.

Study Design

Study Type:
Interventional
Actual Enrollment :
54 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery in Patients With Lumbar Disc Herniations
Study Start Date :
Mar 1, 2010
Actual Primary Completion Date :
Nov 1, 2015
Actual Study Completion Date :
Nov 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Kenalog and Sensorcaine

The following drugs will be administered during a one time injection of the appropriate spinal level based off clinical and radiographic information: Intervention: Kenalog 40 mg/ml and Sensorcaine 0.25% 1cc

Drug: Kenalog and Sensorcaine
Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
Other Names:
  • Kenalog
  • Triamcinolone
  • Sensorcaine
  • Marcaine
  • Bupivacaine hydrochloride
  • Placebo Comparator: Saline

    Saline injections will be used to mimic the Steroid dose

    Drug: Kenalog and Sensorcaine
    Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
    Other Names:
  • Kenalog
  • Triamcinolone
  • Sensorcaine
  • Marcaine
  • Bupivacaine hydrochloride
  • Outcome Measures

    Primary Outcome Measures

    1. Surgical Avoidance [5 years]

      After a minimum 1 year follow-up of an SNRI, a statistical analysis will be conducted to determine group differences in surgical necessity

    Secondary Outcome Measures

    1. Subjective questionnaires [5 Years]

      Each patient will be followed over their course of treatment and information pertaining to their pain and symptoms will be recorded using standard questionnaires such as the SF-36 Questionnaire, the Oswestry Disability Index, and the Visual Analogue Scale. Patient demographics, diagnosis, Worker's Compensation status, spinal levels treatment/outcome, and time from referral to treatment will also be evaluated.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age: 18-65

    • Diagnosed with lower extremity radiculopathy (sciatica) secondary to a lumbar disc herniation

    • Exhausted non-operative measures:

    • Medication has not been helpful in treating the patient's pain/symptoms

    • Modification of daily activities has not been helpful in treating the patient's pain/symptoms

    • Physiotherapy has not been helpful in treating the patient's pain/symptoms.

    • Patient of the Investigator

    • Patient willing to proceed with surgical intervention

    Exclusion Criteria:
    • Age: < 18 or > 65

    • Any patient who has not attempted conservative non-operative treatment for a minimum of 6 weeks

    • Any patient who has not been deemed a surgical candidate

    • Any patient who has a contraindication for surgery

    • Any patient who has a contraindication for Kenalog or Sensorcaine

    • Known sensitivity to medicinal or non-medicinal ingredients

    • Systemic infection

    • Idiopathic thrombocytopenic purpura

    • Cerebrospinal diseases

    • Pregnancy and nursing mothers

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Saint John Regional Hospital Saint John New Brunswick Canada E2L 4L2

    Sponsors and Collaborators

    • Horizon Health Network

    Investigators

    • Principal Investigator: Neil A Manson, MD, Canada East Spine Centre
    • Study Director: Erin E Bigney, MA, Canada East Spine Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr. neil Manson, Orthopaedic surgeon, Horizon Health Network
    ClinicalTrials.gov Identifier:
    NCT01073995
    Other Study ID Numbers:
    • 2009-1376
    First Posted:
    Feb 24, 2010
    Last Update Posted:
    Sep 29, 2016
    Last Verified:
    Sep 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Keywords provided by Dr. neil Manson, Orthopaedic surgeon, Horizon Health Network
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 29, 2016